Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
HURC - one of my other 'value' smallcaps announced a dividend today... not huge at about .8% yield, but I like the confidence and commitment to shareholders.
http://ih.advfn.com/p.php?pid=nmona&article=58030293&symbol=HURC
VSEC - in case anyone following, I sold for 60% gain. Not a rocket like NTEK, but a nice gain for a "safe" dividend-paying company.
INO "Inovio's Universal H7N9 DNA Vaccine Generates First Protective Antibody Responses Against Virulent H7N9 Virus in 100% of Vacc..."
"BLUE BELL, Pa., June 14, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that in a preclinical study of its influenza DNA vaccine against the newly emergent, virulent H7N9 flu virus it achieved immune response levels exceeding what are considered protective levels in other common influenza subtypes. Interim results from a study in mice in a collaboration with researchers from the University of Pennsylvania and Canada's National Microbiology Laboratory in Winnipeg demonstrated that Inovio's H7N9 influenza DNA vaccine achieved greater than 1:40 hemagglutination inhibition (HAI) in 100% of tested animals (n=10), with a geometric mean HAI titer of 1:130 against the A/Anhui/1/13 strain of H7N9 virus. HAI titers at or above 1:40 are considered to denote protection against the influenza virus in humans. These mice received just two vaccinations three weeks apart and the samples tested were from week 5.
Since the first-ever infection of a human with this new influenza subtype in early 2013, the very rapid spread of H7N9 reached a total of 131 confirmed human infections in Asia, with 39 deaths. Experts remain fearful of the possibility of the virus mutating into a form easily transmissible between humans, with the potential to trigger a pandemic. Laboratory tests showed that in some patients the H7N9 virus was resistant to treatment drugs, researchers in China wrote in the medical journal The Lancet last month, adding that their findings were "concerning."
Dr. J. Joseph Kim, Inovio's President and CEO said, "These results show the advantages of Inovio's DNA vaccines versus traditional approaches in two significant ways: how our DNA vaccines can mount a robust defense against emerging potent viral threats with pandemic potential; and, how rapidly we can create a DNA vaccine construct to address a new global threat."
In the preclinical study Inovio researchers constructed a consensus DNA vaccine targeting the HA influenza antigen from sequences collected from several infected H7N9 patients to be broadly protective against all H7N9 viruses. The vaccine was designed, optimized, and manufactured within two weeks, and mice were immunized intramuscularly with two doses followed by electroporation three weeks apart. In an interim analysis, researchers tested sera from the animals against an unmatched H7N9 influenza strain, A/Anhui/1/13. The researchers observed levels of HAI titers, or functional antibodies, that predict protection against the H7N9 virus as well as robust levels of binding antibodies which can block virus entry into host cells as well as inhibit other viral functions.
Generating these very strong immune responses against an unmatched influenza strain adds further to the growing data set indicating the universal protective capability that Inovio's SynCon® DNA vaccines are able to achieve within targeted subtypes. While this study demonstrates that Inovio can respond to an urgent need to address a new subtype of influenza, it also provides further validation of its approach to address the more important need of providing truly preemptive and broad long-term protection against the constant strain mutations that occur within influenza subtypes. The ideal outcome would be to achieve a universal influenza vaccine capable of broad protection against existing and newly emergent unmatched strains across subtypes known to threaten humans.
Using our synthetic consensus design approach, we have created DNA "constructs" for key virus clades (branches) within the Type A subtypes H1N1, H2N2, H3N2, and H5N1 as well as Type B, and target multiple influenza antigens associated with influenza, including the most frequently changing antigen, HA. We can mix and match these individual DNA plasmid constructs as desired to create vaccine candidates. Inovio has previously reported human data indicating protective immune responses against the subtypes H1N1 and H5N1
"
Has an official date been established for TITA hitting walmart shelves?
Go VSEC!!!
I've been holding the whole time as well as all my other miners... got to see some recovery at some point.
AMY got their patent approved today.
Stock-picking supermodel? ... nothing wrong with that! (lol!)
DS ... do you have any insight scoop on the delay (wasn't it supposed to be released in Jan-Feb) and the release date? I've commented before that not seeing TITA at Walmart has been more concerning to me than the audit ... with TITA at Walmart (and also Zombie Wars) and no share price appreciation I might just have to quadruple down!
Sure looking to be a perfect storm brewing!
I'm sure the business and technology is real as stated. Having just heard of this company, however, my conerns would be consumer readiness and acceptance, ability to reach critical mass/scale economies, perhaps a high share price ... that said, I really don't know all the details to make an informed opinion and am certainly open to hearing more!
That low-volume dip at the close sure confirms manipulation to me.
It's all good as the idea is to own under-valued shares which the manipulator has certainly provided!
VRS MD&A - have not read it yet.
https://www.otciq.com/otciq/ajax/showFinancialReportById.pdf?id=106037
Ok, had time to digest a little more ... sorry those questions were a bit obvious from the PR.
It seems like HHSE has 'first mover' advantage to VODWIZ (versus other smaller content providers) ... by consolidating content there is more potential than each studio having their own channel or portal. And HHSE owns the channel ... if/when it reaches critical mass, it would become even more attractive to other content providers.
This type of competitive advantage is not unlike google and their search engine ... as it grows in scale the value increases exponentially. Of course, I'm not saying HHSE is google but I like the strategic thinking behind this. If they can get to the 2500 titles, get some viewers, then there is some very interesting potential...
Seems exciting and I'll have to research more tonight!
I'm trying to get my head around the significance. Is HHSE the first or exclusive content provider to partner with NTEK ... or if there are other content providers?
If there are other providers, is the main benefit that HHSE will have an additional channel (iphone, IPTV, etc). Or, altneratively, (as hinted by these 2500 titles) does the relationship seem deeper such that HHSE will have some role of managing content from perhaps smaller indepedent studios. In other words, I'm trying to understand why the studios with these 2500 titles would not work with NTEK directly??
Of course, this seems great news and I'm sure more details will emerge!
We are lucky to have your DD here ... thanks JFF!
Is there anyway to know the total shares short outstanding? I guess someone with deep pockets could short at these volumes quite easily ... but is playing with fire if the audit comes out!
ADXS - always interesting... seems to be getting more reasonable. If they could raise significant funds then the dilution would not be too bad as there is still huge potential (the science) and perhaps company could get there alone ... with this change, it seems management would have the same skin in the game as shareholders.
http://ih.advfn.com/p.php?pid=nmona&article=57878668&symbol=ADXS
"Advaxis Announces Withdrawal of Proxy Statement Proposal to Amend Its Incentive Plan at This Time"
My appologies for the distraction.
Why don't you let the rest of us know then ... I'm pretty sceptical as you never answered my previous questions either.
I'll look into that one.
My favorite penny stock is HHSE.
There is a LOT of history to this one but they are a movie distributor that has products on the shelves at Walmart (and available at Amazon) but only a $5M market cap.
The negative is that management had promised for financials to be audited ... they are about a year late so the stock has been hammered. With the audit it is expected that the company uplist to a higher exchange.
The positive is that the company, a movie and book distributor, has verified products on the shelves, has not diluted, earnings have accellerated and they were recenlty provided up to a $5M line of credit to fund growth. Their library has 175 movies that they own (including TWELVE with Keifer Sutherland, Toys in the Attic, Turtle the Incredible Jourey, Deceptz which was endored by Snoop Dog, some horror flicks) and the marketcap is only $5M.
Management says they are working (again) on the audit and expect it to be done any time over the next several weeks. If so, this company is probably worth 5 to 10 times the current value.
Can you post the photo and link? I'm quite skeptical given the way you skew your comments all the time, but I'm open minded if there is actual information...
This 'news' is pretty weak considering that 25 units is a highlight of their growing customer base.
Nonetheless, as an investment, I like that investors are probably very frustrated and impatient (low share price and low volume trading) yet the potential remains as when it was trading much higher.
I've tripled my money on a similar Tobin Smith pump ... PLSB which I got at .51 (after a similar decline) which tripled at one point after as customers were eventually signed ... let's see if lightening strikes twice.
I was referring to the low trading volume yesterday but you are absolutely correct ... the bashers are certainly working hard today!
Its frustrating we are not a little higher this week. Yes, we all want the audit, but you'd think we would have inched up a little more given that post-audit should be worth at least 10 cents ...
Anyway, I'm pretty stoked!
BTW ... DID ANYONE HIT WALMART TODAY ... its huge to know if TITA is hitting the shelves and nobody seems to care!!
Hopefully, I'll make it tomorrow...
ADXS "Advaxis Announces Amendment of Proxy Statement Supplement Further Reduction in Share Capital Proposal"
This will result (potentially) in current shareholders controlling 20% of shares ... not sure how much cash they could raise??
http://finance.yahoo.com/news/advaxis-announces-amendment-proxy-statement-120000381.html
Advaxis, Inc., (ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that it has filed a Form DEFR14A with the U.S. Securities and Exchange Commission to amend its Proxy Statement Supplement dated May 22, 2013.
Specifically, Advaxis has further revised Proposal No. 3 to now decrease the proposed total number of authorized shares of common stock post-reverse stock split to 25,000,000 shares (in the earlier proxy supplement, we proposed a total number of 50,000,000 shares of common stock post-reverse stock split).
Advaxis has concluded that stockholder approval of the proposals relating to its certificate of incorporation (Proposal No. 2, the Reverse Stock Split Amendment, and Proposal No. 3, the Authorized Share Decrease Amendment) is more likely to be achieved if Advaxis further decreases the total number of authorized shares of common stock on a post-reverse stock split to 25,000,000 shares of common stock.
“We have revised Proposal 3 in consideration of feedback received from our stockholders. Votes previously cast "in favor" do not need to be re-voted. Votes previously cast "against" can be reversed,” commented Thomas A. Moore, Chairman and CEO of Advaxis. “The Board of Directors and management of the company strongly urge stockholders to vote in favor of this revised proposal. Doing so will position the Company to raise sufficient capital to execute its business plans.”
The Annual Meeting of Stockholders of Advaxis, Inc. will be held on June 14, 2013, at 10:00 a.m., Eastern Daylight Time, at the Princeton Marriott, 100 College Road East, Princeton, New Jersey 08540.
Amendment No. 1 to the Proxy Statement Supplement is being mailed to stockholders of record as of the close of business on April 15, 2013
Agreed, managment has not had a good strategy of communicating the value of the company to shareholders ... they self-imposed deadlines that they've missed, for instance, which takes attention away from their accomplishments.
Ironically, this makes for a great investment where perception lags reality ... I'm liking the value here ... only $5M marketcap!!
Yes, it certainly seems as such.
At least the risk/reward has certainly improved so I'm much more comfortable holding now than before (when I was considering selling after not finding TITA at my Walmart).
HHSE - very muted reaction to the news ... I'm a bit surprised but at least things are looking better!
I think we are saying the same thing ... just different words.
I agree the audit will be huge, the outlook is good, and we've been held back by past mistakes. It's just odd that there are not more 'forward thinkers' out there bidding up the share price right now ... as I said, we are under-the-radar ... but I agree not for long!
Someone sold me 30K shares today (I'm already loaded with a much higher amount) so thanks for that!
I'll be watching to see this updated ...
http://www.tcaglobalfund.com/Press-Releases/
I'm excited too ... been a rocky road but we are getting there!
I'm surprised not more volume following the news, but just proves we are trading under the radar, which is the best opportunity to acquire shares at a discount.
How can this not be good news? Do shorts think they are being dishonest about this loan?
So it seems the preliminary results have been confirmed! My optimisitic scenario that the science is at least valid (unless, as before, some sort of bias was introduced and undetected due to no control group).
What do you all think? ...I'm definately going to hold my reduced position (had sold 1/2 my shares).
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=88326746
Has anyone confirmed TITA is available on the *shelf* of a retailer ... I've seen no such evidence but would be glad to know.
Perhaps by retailers, they mean the their webpages. If so, I don't think that means much as the masses have not heard of this title to search for it ... shelf space, however, means exposure to those same masses.
If I can find TITA at Walmart on June 4th, I think its siginficant. Other than taking their word for it, its the only assurance I know of decent sales for this title.
Redbox in July is a good thing ... thanks for the reminder of this information.
If it's not a bother, it would be great to see a photo...
Thanks Malc ... this is a big deal so I'll be sure to be on the lookout on June 4th (if possible).
If that date is missed and SEC football is not available in August then there really does not seem much chance, even being optimistic. Of course, by then the stock will probably be much lower under that scenario...
At least we'll know soon enough ... won't be another nerve-racking year.
Of course, we are not dead yet ... but the clock is rapidly ticking!
It's all just so confusing...
One question, if not TITA, where is the recent supposed profitability coming from?
They made $400K last Q (to my memory). If they make $5 per unit, then they would have needed to have sold 80K units. There's hardly a comment for TITA on Amazon or Rotten Tomatoes so its very doubtful this came from TITA (although they kept saying sales were very good).
Could the $400K be driven by Deceptz which WAS in Walmart? Walmart has about 9000 locations so if they sold 10 per location then I guess we pass the sniff test?
I'm still holding out that IF Malc is correct (thanks Malc for June 4th date) then TITA could do well. For this small company, I think the best marketing is just getting lots of eyeballs to see the movies on the shelf.
As per the warehouse, I alwasy thought South Florida would be a challenge as the transportation costs would be more significant to ship down here.
Just a wild guess, but -- to save transportation costs -- perhaps large batches are sent by rail such that storage requirements are greater than elsewhere?
Also, storage could be required due to Carribean markets and sending larger shipments at Port Everglades (Fort Lauderdale) and Port of Miami ... not sure such markets are yet significant?
Of course! I dont' shop at those locations regularly, but I'll be sure to keep a lookout.
HHSE - Malc, you had said that TITA should be at Walmart this June, right? I'll be glad to check out some locations nearby but curious if you recall the exact date or anticipate any more delay?
I guess we have the football DVDs coming soon or I'd be getting VERY nervous not finding TITA at Walmart ... I can't see anywhere else driving significant sales as few will be actively seeking out this title ... shelf space is required to get eyeballs and recognition.
PLSB - finally going to be distributed in South Florida ... I'll be glad to actually purchase some Cabana hopefully not too long from now.
http://ih.advfn.com/p.php?pid=nmona&article=57782189&symbol=PLSB
"Pulse Begins Southern Florida Distribution and Warehousing for Cabana(TM)"
The Pulse Beverage Corporation (OTCQB: PLSB) ("Pulse"), makers of PULSE® brand of functional beverages and Cabana™ 100% Natural Lemonade, today announced that it has begun Southern Florida distribution and warehousing for Cabana™ through Dependable Warehousing and Distribution Inc. ("Dependable"), based out of Miami, Florida. Dependable is a supplier of grocery products to more than 400 grocery channels, specializing in the Latin markets such as Presidente and Sedano's Supermarkets among many others. Dependable will also provide warehouse support and be a key distribution point for independent convenience stores for all of Southern Florida and a point of entry into the Caribbean market.
Manny Rivas of Dependable said, "Once we reviewed the Cabana™ brand, with its name and delicious flavors, we were convinced this was a lemonade brand we needed to add to our growing portfolio of products we deliver to our customers throughout South Florida. Being predominate in Latin supermarkets, Cabana™ is the perfect line of lemonade for us to represent."
Paddy Sheya, National Sales Manager for Pulse, stated, "We are very excited to have Dependable join our growing distribution system of 115 US and 4 international distributors. Dependable will provide distribution to over 400 grocery channels as well as provide us with flexible warehouse support to supply future suppliers we are in the process of securing for Southern Florida and the Caribbean."
South Florida resident here ... I don't normally shop at Sedano's or Presidente, but I'll be sure to check out the locations ... anyone have an educated guess how long until Cabana could hit the shelves here?
"Or maybe just as simple as it not being an indepth enough study?"
I'm not sure I'm following in the sense that clinical trial research is not based on depth such as looking more closely at the patients and their response. Given the test was setup properly (as per my previous post) the fundmaental learning is either they recovered by the treatment at a improved rate or they didn't ... given the good results, the only issue is statistical power as per the correponding sample size.
If by 'in-depth' you are suggesting there could have been a larger sample size, then -- yes -- I agree that it could have helped. However, I was thinking along the lines already way back when, at the time I posted here tests of statistical significance. I forget the exact details offhand, but -- given the sample sizes -- the impact of the treatment was definately statistically significant. It seemed very unlikely the results were by random chance.
I see only three scenarios to explain the favorable preliminary India results:
1. Just by random luck -- say a 1 in 100 chance (I forget the calculated p-value) -- the patients selected for the trial just happened to be prone to recover (not due to the treatment). If the trial was to be repeated, similar results would be very unlikely (lightening striking the same place twice) . This being said, I would make the same bet again and again as the probabilities were surely in our favor.
2. The results, not being a random test design, were biased due to factors previously mentioned. This could have been intentional or not. This seems unlikely, however, as would not the FDA be aware of some bias of having the test in India. Would managment be this good at finding some way to fool everyone??
3. The results reflect a geniunely effective treatment. Here, there remains all the issues of dilution, poor-communication, etc, but we still have a shot as here the science itself is valid. In this case, why would managment dilute when good results are just around the corner?
I get confused as all three results are unlikely! But I can't imagine any other scenarios...
Yes, I wish I had more experience in the area but I know with a random test design nothing would have been left to doubt (except for small sample size issues).
In this case, perhaps India has a younger population (that generally recover more easily), the prior care is not as good (such that care concurrent with the treatment is effective), or even better genetics of Indians? Of course, I'm just making this stuff up but perhaps such factors were manipulated to make the results seem good.
I'm still in INO and actually up about 30-40% ... I like they have some revenues from goverment contracts, the proporitary electroportion technology (which could have value independent to the trial results), and many trials. However, on any further pop I'm going to sell some shares to be safe.
I'm giving it the rest of this year to see if any of my "catalyst-driven" stocks do well. If we don't get an HHSE audit, Aura does not get some decent progress, clinical trial results for ADXS continue to be unfavorable, Veolia does not start liscencing/implementing Orbite's technology, etc etc, the I'm definately going to reallocate most of my portfolio to value-oriented plays and trading based on low-volume dips.